- Home
- HRMY
as 07-11-2025 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $54.44 | AVG Volume (30 days): | 642.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.62 | EPS Growth: | 13.13 |
| 52 Week Low/High: | $26.47 - $41.61 | Next Earning Date: | 08-05-2025 |
| Revenue: | $744,852,000 | Revenue Growth: | 20.62% |
| Revenue Growth (this year): | 20.1% | Revenue Growth (next year): | 18.01% |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
Argus Research
17 days ago
HRMY: What does Argus have to say about HRMY?
Insider Monkey
17 days ago
Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY)
Business Wire
a month ago
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
Argus Research
a month ago
HRMY: Rating decreased to a HOLD
Insider Monkey
a month ago
Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory
TipRanks
a month ago
Harmony Biosciences settles generic drug litigation, strengthens patent
MT Newswires
a month ago
Harmony Biosciences, Lupin Settle Lawsuit Over Generic Version of Narcolepsy Drug
Business Wire
a month ago
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.